Clinical Trials
6 trialsNCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT05166577 2025-03-12
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Viracta Therapeutics, Inc.
Phase 1 Terminated
NCT03674567 2025-01-24
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
Phase 1/2 Completed
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT03809624 2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1 Terminated
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed